Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid (Q24246441)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

1 reference

title

Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

E H Walters

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

T J Lasserson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

J A E Walters

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

24 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

CD001385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-du

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Sensitivity of quality of life domains and constructs to longitudinal change in a clinical trial comparing salmeterol with placebo in asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromogl

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Serious asthma exacerbations in asthmatics treated with high-dose formoterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Formoterol Delivered via the Dry Powder Aerolizer® Inhaler Versus Albuterol MDI and Placebo in Mild-to-Moderate Asthma: A Randomized, Double-Blind, Double-Dummy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effect of salmeterol on seasonal changes in airway responsiveness and exhaled nitric oxide in pollen-sensitive asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Comparison of salmeterol with placebo in mild asthma: effect on peripheral blood phagocyte function and cytokine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Achieving guideline-based asthma control: does the patient benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A randomized, double-blind trial of the effect of treatment with formoterol on clinical and inflammatory parameters of asthma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A comparison of regular salmeterol vs 'as required' salbutamol therapy in asthmatic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Formoterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

β2-Adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma☆☆☆★★★

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol tachyphylaxis in steroid treated asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol in paediatric asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effectiveness and safety of salmeterol in nonspecialist practice settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Prevention of exercise induced asthma by inhaled salmeterol xinafoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Long-term efficacy of formoterol compared to salbutamol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A 4-week comparison of salmeterol and terbutaline in adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Twelve months, treatment with inhaled salmeterol in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Potential masking effects of salmeterol on airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Comparison of the effects of salmeterol and formoterol in patients with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effect of formoterol, a long-lasting beta 2-adrenoceptor agonist, against methacholine-induced bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Asthma quality of life during 1 year of treatment with budesonide with or without formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Comparison of the Bronchodilator Effect of Inhaled Short- and Long-Acting beta(2)-Agonists in Children with Bronchial Asthma: A Randomised Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

A one-week dose-ranging study of inhaled salmeterol in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Are asthma medications and management related to deaths from asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Interactions of glucocorticoids and beta 2-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Long- versus short-acting beta 2-agonists. Implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Development of child-centered disease-specific questionnaires for living with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Functional antagonism: tolerance produced by inhaled beta 2 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

The reproducibility of the Childhood Asthma Questionnaires: measures of quality of life for children with asthma aged 4-16 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Global initiative for asthma (GINA) and its objectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

The effect of long-acting beta2-agonists on airway inflammation in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Long-acting inhaled beta(2)-agonist therapy in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effects of genetic polymorphism on ex vivo and in vivo function of beta2-adrenoceptors in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Long-acting inhaled beta2-agonists in asthma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

An explanation of the asthma paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

The use of beta-agonists and the risk of death and near death from asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Clinical pharmacology of long-acting beta-receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Interactions between corticosteroids and beta agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Discriminative aspects of two generic and two asthma-specific instruments: relation with symptoms, bronchodilator use and lung function in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Do long-acting beta2-adrenergic agonists deserve a different place in guidelines for the treatment of asthma and COPD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Effects of house dust mite avoidance measures on Der p 1 concentrations and clinical condition of mild adult house dust mite-allergic asthmatic patients, using no inhaled steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Respiratory arrests in young asthmatics on salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Delivering effective asthma care - how do we implement asthma guidelines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Long-acting beta(2)-agonists in childhood asthma: Don't change a winning team (yet)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Effect on airway responsiveness of six weeks treatment with salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Efficacy and safety of salmeterol in childhood asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Protection against allergen-induced asthma by salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Exacerbations of asthma in patients on salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Asthma exacerbations in patients taking regular salmeterol, or salbutamol for symptoms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Regular inhaled salbutamol and airway responsiveness to allergen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Respiratory arrests in young asthmatics on salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Effects of treatment with formoterol on bronchoprotection against methacholine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Salmeterol does not cause tolerance during long-term asthma therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

The Living with Asthma Questionnaire

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

The rising prevalence of asthma in young Melbourne adults is associated with improvement in treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

The long‐acting β2‐agonist salmeterol xinafoate: effects on airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Altered cardiovascular autonomic regulation after salmeterol treatment in asthmatic children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Effect of long-term salmeterol treatment on exercise-induced asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Comparison of beclomethasone, salmeterol, and placebo in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

The efficacy and safety of inhaled salmeterol 50 microg bd in older patients with reversible airflow obstruction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Functional status II(R). A measure of child health status.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

The pharmacologic and clinical properties of Oxis (formoterol) Turbuhaler

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Short-term effects of budesonide, nedocromil sodium and salmeterol on bronchial hyperresponsiveness in childhood asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Guidelines for the management of asthma: a summary. British Thoracic Society and others

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Comparison of an inhaled corticosteroid (triamcinolone acetonide) to a long-acting bronchodilator (salmeterol), the combination, and placebo in mild-moderate adult asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Prolonged Protection against Methacholine-induced Bronchoconstriction by the Inhaled β2-Agonist Formoterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Overnight protection by inhaled salmeterol on exercise-induced asthma in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Comparison of asthma prevalence in the ISAAC and the ECRHS. ISAAC Steering Committee and the European Community Respiratory Health Survey. International Study of Asthma and Allergies in Childhood

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Rapid onset of tolerance to the bronchoprotective effect of salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Asthma mortality and beta-agonists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Effect of inhaled salmeterol on sulfur dioxide-induced bronchoconstriction in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

What is a spontaneous pneumothorax?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001385.PUB2

7 January 2021

10.1002/14651858.CD001385.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253458%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference